Anti-Human Thymocyte Immunoglobulin, Rabbit

DRUG2 trials

Sponsors

Universitaire Ziekenhuizen KU Leuven, Peking Union Medical College Hospital

Conditions

Aplastic AnemiaDiabetes Mellitus, Type 1

Phase 2

MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

CompletedNCT04509791

Universitaire Ziekenhuizen KU LeuvenDiabetes Mellitus, Type 1

Start: 2020-11-24End: 2024-12-16Updated: 2025-01-10

Phase 4

CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly

CompletedNCT05996393

Peking Union Medical College HospitalAplastic Anemia

Start: 2023-09-15End: 2025-02-27Updated: 2025-04-30

Related Papers

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

2025-09-183 citations

Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes

JCI Insight2023-07-1130 citations